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Advances in diagnosis and treatment of perinatal HIV infec-tion in the United States have significantly improved life 
expectancy.1,2 However, prolonged exposure to HIV and highly 
active antiretroviral therapy (HAART) has been associated 
with long-term complications. Atherosclerotic cardiovascular 
disease (CVD) risk factors, including hyperlipidemia, lipodys-
trophy, diabetes mellitus, and hypertension, have increased in 
prevalence and severity with the advent of HAART.3–15 These 
CVD risk factors have been studied in adults,3–6 with expanding 
research in children.7–15 Potential contributors to CVD risk and 
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clinical CVD events in adult HIV-infected populations include 
traditional risk factors such as male sex and lifestyle habits (eg, 
exercise, diet, and smoking), as well as HIV-specific risk fac-
tors, particularly exposure to HAART and specific antiretroviral 
drugs, including protease inhibitors such as indinavir and lopi-
navir/ritonavir and nucleoside reverse transcriptase inhibitors 
such as stavudine, didanosine, and abacavir.3–6 In children, pro-
tease inhibitors have been primarily associated with CVD risk 
factors, although some studies note hypercholesterolemia and 
lipodystrophy with nucleoside reverse transcriptase inhibitors, 
particularly stavudine.7–15
The atherosclerotic disease process begins at an early age, 
with severity and progression into adulthood associated with 
established CVD risk factors.16–19 Therefore, CVD risk should 
be tracked from childhood on. To identify and motivate high-
risk children who may benefit from early interventions, it is 
clinically useful to obtain a measure of aggregate CVD risk by 
the use of a scoring system that sums the risks associated with 
each individual risk factor.20 The Framingham Risk Calculator 
is among the most widely accepted instruments in predicting 
the 10-year overall risk of coronary heart disease based on a 
simple, validated algorithm that includes demographics, life-
style behaviors, blood pressure, and lipid testing.21 However, 
this risk score has not been validated for an adolescent popula-
tion. The Pathobiological Determinants of Atherosclerosis in 
Youth (PDAY) scoring system may be useful for measuring 
long-term CVD risk in youth and young adults by identifying 
those with current advanced atherosclerosis.18
Developed with autopsy data from >1100 individuals 15 to 
34 years of age who died of external causes, the PDAY scor-
ing system estimates the risk of currently having an advanced 
atherosclerotic lesion in the coronary arteries (CA) or the 
abdominal aorta (AA) relative to an individual of the same 
age and sex without any CVD risk factors.18 The CA risk score 
predicts coronary artery calcium and carotid artery intima-
media thickness measures of atherosclerosis in a number of 
 population-based cohorts.22–24 The risk factors included in 
the CA and AA scores are also associated with noninvasive 
measures of atherosclerosis among HIV-infected children.25,26 
Thus, as a validated measure of the atherosclerotic disease pro-
cess, we used PDAY scores to describe CVD risk in perinatally 
HIV-infected adolescents enrolled in the Pediatric HIV/AIDS 
Cohort Study (PHACS). We additionally identified demo-
graphic and  HIV-specific predictors of high scores and evalu-
ated trends in scores over the 4-year study follow-up period.
Methods
The Adolescent Master Protocol of the PHACS was designed to eval-
uate the impact of HIV infection and antiretroviral therapy on youth 
with perinatal HIV infection. Between March 2007 and December 
2009, 451 infected and 227 uninfected youth from 15 study sites in 
the United States were enrolled if they were born to HIV-infected 
mothers, were 7 to 16 years of age, and had complete medical his-
tory of antiretroviral therapy use, plasma HIV RNA (viral load) con-
centrations, and lymphocyte subset measurements since birth. The 
Adolescent Master Protocol was approved by the institutional review 
boards at the Harvard School of Public Health and at each partici-
pating site. Written informed consent was obtained from each par-
ticipant’s parent or legal guardian. Assent was obtained from child 
participants according to local institutional review board guidelines. 
Of the 451 infected participants, 225 were in the validated age range 
for the PDAY score (≥15 years) as of April 1, 2012, and 165 had the 
clinical measures needed to calculate the PDAY score for at least 1 
time point (Table I in the online-only Data Supplement).
For each participant, CA and AA risk scores were calculated at 
each annual visit with available clinical data after reaching 15 years 
of age by summing the scores associated with modifiable measures of 
atherosclerotic risk, including lipids, glucose, smoking, blood pres-
sure, and obesity defined by body mass index.18 In the PDAY study, 
CA and AA risk scores ≥1 were shown to indicate at least an 18% 
(95% confidence interval, 14–22) or 29% (95% confidence interval, 
23–35) increased odds of currently having an advanced atheroscle-
rotic lesion in the CAs or AA, respectively, relative to a score of 0.18
Fasting serum and plasma were drawn annually to measure levels 
of total and high-density lipoprotein (HDL) cholesterol and glucose, 
respectively. Hyperglycemia was defined as a fasting plasma glu-
cose concentration ≥126 mg/dL, a diagnosis of diabetes mellitus, or 
reporting the use of medication to treat diabetes mellitus. The serum 
thiocyanate measure of smoking used in the development of the 
PDAY scores closely correlated with smoking an average of 1 pack 
per day (ie, heavy smoking).27 Information on smoking an average 
of at least 1 pack per day in the past 3 months was collected with an 
Audio Computer-Assisted Self-Interview. Hypertension was defined 
as an average systolic or diastolic blood pressure ≥95th percentile for 
age, sex, and height at ≥3 clinic visits.28
Demographic characteristics considered as potential predictors 
of CA and AA scores included age, sex, and race/ethnicity. HIV-
specific clinical characteristics included measures of disease sever-
ity: CD4 count, HIV viral load, and Centers for Disease Control and 
Prevention clinical classification for HIV disease (N/A=not/mildly 
symptomatic, B=moderately symptomatic, C=severely symptomatic/
meets the case definition for AIDS),29 and antiretroviral therapy pre-
viously associated with CVD risk: HAART, any ritonavir-boosted 
protease inhibitor, lopinavir/ritonavir, indinavir, didanosine, abacavir, 
stavudine, zidovudine, lamivudine, and tenofovir disoproxil fuma-
rate.3–15 All characteristics were collected through either self-report 
(eg, race/ethnicity) or medical chart abstraction (eg, immunologic, 
virological, and antiretroviral characteristics). Current measures were 
those closest to the most recent visit at which a PDAY score could be 
calculated within 90 days before to 7 days after the visit. Nadir CD4 
count and peak viral load were defined as the lowest CD4 count and 
the highest viral load documented before or at the most recent visit 
with a PDAY score. HAART was defined as concomitant use of at 
least 3 drugs from at least 2 classes of antiretrovirals. Antiretroviral 
use was classified as use at the most recent visit (ie, current use), prior 
or ever use, and cumulative duration of use up to and including the 
most recent visit with a PDAY score.
Statistical analyses were conducted separately for CA and AA 
scores. Demographic and HIV-specific characteristics were compared 
among children with low scores (≤0) and high scores (≥1) at their 
most recent visit by use of the Wilcoxon rank-sum test or the Fisher 
exact test as appropriate. The cutoff for low versus high scores was 
based on the distribution of scores in the study population and was 
consistent with definitions of low risk used in previous studies.22–24 To 
identify significant predictors of a high-risk score, univariable predic-
tors of a high score at the P<0.10 level were included in a multivari-
able logistic regression model. Among highly correlated univariable 
predictors, the predictor with the highest univariable c statistic was 
included in the final multivariable model. Sensitivity analyses were 
conducted with the study population restricted to virologically sup-
pressed (HIV viral load ≤400 copies/mL) participants. Mixed-effects 
models with time as the independent variable and an assumed com-
pound symmetry correlation structure were used to describe changes 
in CA and AA scores over the study follow-up period, starting with 
the baseline visit and including all study visits at which a PDAY score 
could be calculated. All analyses were conducted with SAS version 
9.2 (SAS Institute, Cary, NC).
Results
The 165 perinatally HIV-infected adolescents in the study popu-
lation were 15 to 19 years old (median age, 16.7 years) at their 
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most recent visit with a PDAY score (Table 1).  Forty-nine percent 
were male. Sixty-eight percent were self-identified as black and 
24% as Hispanic. At their most recent visit with a PDAY score, 
the majority (57%) of the adolescents had CD4 counts >500 
cells/mm3, but a large proportion (41%) had a history of immu-
nosuppression as evidenced by a low nadir CD4 count (<200 
cells/mm3). A similar pattern of disease severity over time was 
observed with HIV viral load in which 59% of the study popu-
lation was virologically suppressed (≤400 copies/mL) at their 
most recent visit, but 68% had a history of viral load >100 000 
copies/mL. Almost all of the adolescents had prior HAART 
exposure (97%). Seventy-four percent had been exposed to a 
boosted protease inhibitor regimen, with 58% currently on a 
boosted protease inhibitor as of their most recent visit.
Figure 1 shows the distribution of the most recent CA and 
AA scores in the study population. Forty-eight percent had 
CA scores ≥1, with 24%, 16%, and 12% having CA scores 
≥2, ≥3, and ≥4, respectively. High CA scores were attributed 
primarily to increased levels of non-HDL cholesterol, with 
additional risk from low levels of HDL cholesterol and high 
body mass index (Table 2 and Table II in the online-only Data 
Supplement). Few adolescents were defined as hypertensive 
(1%) or hyperglycemic (1%), and none were defined as heavy 
smokers. Two adolescents with CA scores ≥10 had elevated 
levels of non-HDL cholesterol in the range of 160 to 189 mg/
dL and were obese (body mass index >30 kg/m2). Twenty-four 
percent of the study population had AA scores ≥1. Ten percent, 
Table 1. Demographic and Clinical Characteristics of the 165 
Perinatally HIV-Infected Children in the Study Population
Characteristic Total (n=165)
Current* age, median (q1, q3), y 16.7 (15.9, 17.8)
Female, n (%) 84 (51)
Race/ethnicity, n (%)
  White/other 12 (7)
  Black 113 (68)
  Hispanic 39 (24)
  Missing 1 (1)
Current* CD4 count, n (%)
  <200 cells/mm3 19 (12)
  200–500 cells/mm3 46 (28)
  >500 cells/mm3 94 (57)
  Missing 6 (4)
Nadir CD4 count, n (%)
  <200 cells/mm3 68 (41)
  200–500 cells/mm3 81 (49)
  >500 cells/mm3 16 (10)
Current* HIV viral load, n (%)
  ≤400 copies/mL 98 (59)
  401–5000 copies/mL 25 (15)
  >5000 copies/mL 35 (21)
  Missing 7 (4)
Peak HIV viral load, copies/mL, n (%)
  <10 000 copies/mL 7 (4)
  10 000–100 000 copies/mL 45 (27)
  >100 000 copies/mL 113 (68)
Current* CDC category, n (%)
  N/A 59 (36)
  B 55 (33)
  C 51 (31)
HAART
  Current* use, n (%) 143 (87)
  Ever use, n (%) 160 (97)
  Cumulative duration of use, median (q1, q3), y 11.0 (7.7, 12.5)
Boosted protease inhibitor
  Current* use, n (%) 95 (58)
  Ever use, n (%) 122 (74)
  Cumulative duration of use, median (q1, q3), y 4.0 (0.0, 7.4)
Lopinavir/ritonavir
  Current* use, n (%) 48 (29)
  Ever use, n (%) 95 (58)
  Cumulative duration of use, median (q1, q3), y 1.4 (0.0, 4.8)
Indinavir
  Current* use, n (%) 0 (0)
  Ever use, n (%) 18 (11)
  Cumulative duration of use, median (q1, q3), y 0.0 (0.0, 0.0)
Didanosine
  Current* use, n (%) 17 (10)
  Ever use, n (%) 138 (84)
  Cumulative duration of use, median (q1, q3), y 3.3 (1.0, 7.1)
(Continued)
Abacavir
  Current* use, n (%) 46 (28)
  Ever use, n (%) 79 (48)
  Cumulative duration of use, median (q1, q3), y 0.0 (0.0, 3.3)
Stavudine
  Current* use, n (%) 11 (7)
  Ever use, n (%) 136 (82)
  Cumulative duration of use, median (q1, q3), y 6.1 (1.8, 8.5)
Zidovudine
  Current* use, n (%) 18 (11)
  Ever use, n (%) 145 (88)
  Cumulative duration of use, median (q1, q3), y 3.7 (1.6, 7.4)
Lamivudine
  Current* use, n (%) 53 (32)
  Ever use, n (%) 149 (90)
  Cumulative duration of use, median (q1, q3), y 5.7 (2.8, 9.4)
Tenofovir disoproxil fumarate
  Current* use, n (%) 80 (48)
  Ever use, n (%) 100 (61)
  Cumulative duration of use, median (q1, q3), y 0.9 (0.0, 3.2)
CDC indicates Centers for Disease Control and Prevention (N/A, not/mildly 
symptomatic; B, moderately symptomatic; C, severely symptomatic/AIDS 
definition); HAART, highly active antiretroviral therapy; q1, quartile 1; and q3, 
quartile 3.
*Current is defined as the measurement at the most recent visit.
Table 1. Continued
Characteristic Total (n=165)
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3%, and 1% had AA scores ≥2, ≥3, and ≥4, respectively. High 
AA scores were also attributable primarily to dyslipidemia.
Univariable predictors of CA scores ≥1 versus ≤0 at the 
P<0.10 level included male sex, Centers for Disease Control 
and Prevention category C disease (AIDS-defining condi-
tions), current use of a boosted protease inhibitor, prior use 
of a boosted protease inhibitor, longer cumulative duration of 
boosted protease inhibitor use, current use of lopinavir/ritona-
vir, prior use of lopinavir/ritonavir, and no prior use of tenofo-
vir (Table 3 and Table III in the online-only Data Supplement). 
Current use, ever use, and duration of use of a boosted prote-
ase inhibitor and current and ever use of lopinavir/ritonavir are 
highly correlated. Thus, the one with the highest c statistic was 
entered into the final multivariable model. Male sex, Centers 
for Disease Control and Prevention category C disease (rela-
tive to category B), longer cumulative duration of boosted 
protease inhibitor use, and no prior use of tenofovir were all 
significant predictors of CA scores ≥1 at P<0.05 with a final 
model c statistic of 0.74 (Table 4). Results were consistent 
among the virologically suppressed subset of the population 
(Table IV in the online-only Data Supplement).
Univariable predictors of AA scores ≥1 versus 0 at the 
P<0.10 level included current HIV viral load ≤400 copies/
mL, Centers for Disease Control and Prevention category 
C disease, current HAART use, current and prior use of a 
boosted protease inhibitor, a longer cumulative duration of 
boosted protease inhibitor use, current and prior use of lopina-
vir/ritonavir, a longer cumulative duration of lopinavir/ritona-
vir use, current abacavir use, current lamivudine use, and no 
prior tenofovir use (Table 3). In the final model, current HIV 
virological suppression (≤400 versus 401–5000 copies/mL), 
Centers for Disease Control and Prevention clinical category 
C disease (relative to category B), and longer cumulative 
duration of boosted protease inhibitor use significantly pre-
dicted AA scores ≥1 at P<0.05 with a total model c statistic of 
0.84 (Table 5). Results of sensitivity analyses were consistent 
with those observed in the overall population (Table V in the 
online-only Data Supplement).
Figure 2 shows the mean PDAY scores during the 4-year 
study follow-up period (mean follow-up of study population, 
2.5 years). The slope of the CA scores was 0.10 per year and 
did not change significantly over time (95% confidence inter-
val, −0.05 to 0.24; P=0.19). AA scores were also stable over 
time, with a slope of 0.03 per year (95% confidence interval, 
−0.03 to 0.08; P=0.34).
Discussion
Previous studies of perinatally HIV-infected children raised 
concern about increased CVD risk resulting from distribu-
tions of individual risk factors in this population.7–15 Our study 
uniquely sought to measure and describe aggregate CVD risk 
resulting from the combination of risk factors in perinatally 
HIV-infected youth by using the validated PDAY scoring 
system, which integrates individual risk factors into a single 
score for the CA and AA. Forty-eight percent of perinatally 
HIV-infected youth had high scores, with 12% having scores 
associated with combinations of dyslipidemia plus high indi-
vidual score risk factors such as obesity, high blood pressure, 
and hyperglycemia.
Twenty-two percent of our study population had non-HDL 
cholesterol levels ≥130 mg/dL, and 29% had HDL cholesterol 
<40 mg/dL. These findings are consistent with the high preva-
lence of dyslipidemia observed in perinatally HIV-infected 
cohorts compared with national youth estimates.7–10,13,30 The 
prevalence of obesity in our study population was 13%, which 
is lower than the 18% prevalence of obesity recently reported 
among adolescents in the United States.31 This is consistent 
with previous studies.9,10 However, a recent study showed that 
HIV-infected children have trends in obesity similar to those 
of the general population.32 The combination of dyslipidemia 
and obesity in the perinatally HIV-infected population would 
further the concern for premature atherosclerotic CVD.
Male participants in our study population were more likely 
to have high CA scores compared with female participants. 
Among studies of CVD risk factors that evaluated sex differ-
ences among perinatally HIV-infected adolescents, 1 study 
found significantly higher cholesterol levels in male relative to 
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Figure 1. Distribution of Pathobiological 
Determinants of Atherosclerosis in Youth (PDAY) 
risk scores in the study population.
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female participants.7 Three studies found no sex differences in 
lipodystrophy or insulin resistance,12–14 whereas 3 other stud-
ies found female participants to have a body fat distribution 
associated with increased CVD risk.10,11 Independent of their 
CVD risk resulting from traditional risk factors, male partici-
pants had a higher risk of having a lesion in the CA compared 
with female participants in the PDAY study.18
A history of an AIDS-defining event also predicted higher 
PDAY scores in our study. Low levels of HDL cholesterol, 
often associated with inflammation and endothelial acti-
vation, are reported in HIV-infected adults with AIDS or 
untreated HIV infection.33,34 In addition, independent of tra-
ditional CVD risk factors, HIV disease severity is correlated 
with higher levels of T-cell activation, which is further associ-
ated with the presence of subclinical carotid artery lesions.35 
In our study, suppressed HIV viral loads also predicted high 
PDAY scores for the AA relative to HIV viral loads in the 
range of 401 to 5000 copies/mL. These effects may reflect 
toxicities associated with exposure to antiretroviral medi-
cations because children currently on effective therapy are 
likely to have suppressed viral loads. Our observation is also 
consistent with studies among HIV-infected adults that show 
that the risk for vascular disease with ongoing inflammation 
is still increased in the presence of viral suppression.35
As expected from prior studies in HIV-infected youth,7–15 
boosted protease inhibitor use was a strong predictor of high 
CA and AA scores in our study population. Protease inhibi-
tors promote hyperlipidemia by upregulating fatty acid and 
cholesterol biosynthesis and secretion and by increasing lipo-
protein production in the liver.36 Protease inhibitors can also 
suppress leptin expression and glucose transporter type 4 
activity in adipocytes, thereby promoting lipodystrophy, insu-
lin resistance, and diabetes mellitus.36 Although 5 to 8 years 
of exposure to boosted protease inhibitors predicted high CA 
Table 2. Distribution of Modifiable Atherosclerotic Risk Factors Included in the PDAY 
Scoring System Among the 165 Perinatally HIV-Infected Children in the Study Population at 
Their Most Recent Visit With a PDAY Score
Modifiable Risk Factor Coronary Arteries Points* Abdominal Aorta Points* n (%)
Non-HDL cholesterol
  <130, mg/dL 0 0 128 (78)
  130–159, mg/dL 2 1 24 (14)
  160–189, mg/dL 4 2 12 (7)
  190–219, mg/dL 6 3 1 (1)
  ≥220, mg/dL 8 4 0 (0)
HDL cholesterol
  <40, mg/dL 1 0 48 (29)
  40–59, mg/dL 0 0 96 (58)
  ≥60, mg/dL −1 0 21 (13)
Heavy smoking†
  No 0 0 165 (100)
  Yes 1 4 0 (0)
Blood pressure‡
  Not hypertensive 0 0 163 (99)
  Hypertensive 4 3 2 (1)
Body mass index (obesity)
  Male
   ≤30, kg/m2 0 0 74 (45)
   >30, kg/m2 6 0 7 (4)
  Female
   ≤30, kg/m2 0 0 70 (42)
   >30, kg/m2 0 0 14 (9)
Glycemia§
  Not hyperglycemic 0 0 163 (99)
  Hyperglycemic 5 3 2 (1)
BMI indicates body mass index; HDL, high-density lipoprotein; and PDAY, Pathobiological Determinants of 
Atherosclerosis in Youth.
*Adapted from McMahan et al 2005.18 Copyright © 2005, American Medical Association. All rights reserved.
†Heavy smoking was defined as smoking an average of at least 1 pack per day in the past 3 months.
‡Hypertensive was defined as an average systolic or diastolic blood pressure ≥95th percentile for age, sex, and 
height at ≥3 visits.
§Hyperglycemic was defined as a fasting plasma glucose concentration ≥126 mg/dL, a diagnosis of diabetes 
mellitus, or the use of diabetes medication.
 by guest on D
ecem
ber 23, 2016
http://circ.ahajournals.org/
D
ow
nloaded from
 
Patel et al  Cardiovascular Disease Risk and HIV-Infected Youth  1209
and AA scores, >8 years of exposure did not. This may be 
attributable to a lack of power to observe a significant effect 
resulting from few observed events among those with >8 years 
of exposure. Alternatively, our results may reflect the clinician 
practice of switching children with preliminary indications 
of hyperlipidemia from boosted protease inhibitors to more 
lipid-friendly regimens.
A recent study of HIV-infected adults found that teno-
fovir was significantly associated with the progression of 
subclinical atherosclerosis, mediated perhaps through the 
lack of reduction in plasma monocyte chemotactic protein 
1 levels relative to therapy with abacavir and lamivudine.6 
Among our population of perinatally HIV-infected adoles-
cents, however, tenofovir use predicted a lower likelihood of 
having high CA scores, consistent with other studies among 
HIV-infected adults showing improvement in dyslipidemia 
and arterial stiffness with nucleoside reverse transcriptase 
inhibitor switches to tenofovir.37 With these contrasting 
results, the association between tenofovir and CVD requires 
further investigation.
Over our 4-year study follow-up, there were no significant 
changes in CA or AA scores. We may be observing the con-
sistent tracking of CVD risk factors over time, or the duration 
of follow-up of our cohort may not have been sufficiently long 
to observe the acquisition of more adult lifestyle risk factors 
such as smoking and physical inactivity. Continued follow-up 
of adolescents in our study as they age into adulthood is neces-
sary to better evaluate longitudinal trends in CVD risk and to 
identify associated factors.
Our study had some limitations. We were unable to vali-
date the PDAY scoring system against noninvasive measures 
of atherosclerosis or CVD events. The Adolescent Master 
Protocol did not include these measures, and there is a low 
probability of observing CVD events in our relatively young 
study population. The CA and AA risk scores used in this 
study were developed from autopsy data, so the definitions 
Table 3. Univariable Predictors of PDAY Risk Scores Among the 165 Perinatally HIV-Infected Children in the Study Population at 
Their Most Recent Visit
Coronary Arteries PDAY Score Abdominal Aorta PDAY Score
Characteristic ≤0 (n=85) ≥1 (n=80) P Value* c Statistic 0 (n=126) ≥1 (n=39) P Value* c Statistic
Female, n (%) 50 (59) 34 (43) 0.04 0.58 NS
Current† HIV viral load, n (%) 0.01 0.64
  ≤400 copies/mL NS 68 (54) 30 (77)
  401–5000 copies/mL 24 (19) 1 (3)
  >5000 copies/mL 29 (23) 6 (15)
  Missing 5 (4) 2 (5)
Current† CDC category, n (%) 0.05 0.60 0.06 0.61
  N/A 33 (39) 26 (33) 47 (37) 12 (31)
  B 33 (39) 22 (28) 46 (37) 9 (23)
  C 19 (22) 32 (40) 33 (26) 18 (46)
HAART
  Current† use, n (%) NS 105 (83) 38 (97) 0.03 0.57
Boosted protease inhibitor
  Current† use, n (%) 41 (48) 54 (68) 0.02 0.60 63 (50) 32 (82) <0.01 0.66
  Ever use, n (%) 56 (66) 66 (83) 0.02 0.58 88 (70) 34 (87) 0.04 0.59
  Cumulative duration of use, 
median (q1, q3), y
2.8 (0.0, 7.5) 4.8 (1.3, 7.3) 0.09 0.63 3.2 (0.0, 7.3) 6.0 (4.5, 8.2) <0.01 0.71
Lopinavir/ritonavir
  Current† use, n (%) 18 (21) 30 (38) 0.03 0.58 26 (21) 22 (56) <0.01 0.68
  Ever use, n (%) 42 (49) 53 (66) 0.04 0.58 66 (52) 29 (74) 0.02 0.61
  Cumulative duration of use, 
median (q1, q3), y
NS 0.4 (0.0, 4.1) 4.5 (0.0, 6.8) <0.01 0.66
Abacavir
  Current† use, n (%) NS 29 (23) 17 (44) 0.02 0.60
Lamivudine
  Current† use, n (%) NS 35 (28) 18 (46) 0.05 0.59
Tenofovir disoproxil fumarate
  Ever use, n (%) 58 (68) 42 (53) 0.06 0.58 81 (64) 19 (49) 0.09 0.58
CDC indicates Centers for Disease Control and Prevention (N/A, not/mildly symptomatic; B, moderately symptomatic; C, severely symptomatic/AIDS definition); 
HAART: highly active antiretroviral therapy; NS, not significant at P<0.10; and PDAY, Pathobiological Determinants of Atherosclerosis in Youth.
*Wilcoxon test P value for continuous variables and the Fisher exact test P value for categorical variables.
†Current is defined as the measurement at the most recent visit.
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of some of the risk factors (eg, hypertension) were adapted 
using measures available in clinical practice. The difference 
in definitions, therefore, may not directly correlate with the 
odds ratio interpretations of the PDAY risk scores as stated 
by McMahan et al.18 We used the PDAY score as an estimate 
of the aggregate atherosclerotic CVD risk in our popula-
tion. The PDAY score, however, may underestimate the risk 
of atherosclerotic lesions in this population because of the 
independent effects of HIV and antiretroviral therapy on the 
development and progression of atherosclerosis.35 Studies 
among HIV-infected adults suggest that risk scores incorpo-
rating both traditional and HIV-specific parameters may better 
predict CVD risk in  HIV-infected populations.38,39 Although 
our study has a relatively small sample size compared with 
other studies that have used PDAY scores,22–24 it represents 
an understudied population of perinatally HIV-infected youth 
aging into young adulthood.
Conclusions
A substantial proportion of perinatally HIV-infected adoles-
cents have PDAY scores reflecting increased aggregate ath-
erosclerotic risk factor burden. PDAY scores may be useful 
Table 4. Predictors of Coronary Arteries PDAY Risk Scores 
≥1 Versus ≤0 Among the 165 Perinatally HIV-Infected Children 
in the Study Population at Their Most Recent Visit
Characteristic
Multivariable
Odds Ratio (95% CI) P Value
Sex 0.01
  Male 2.47 (1.24–4.92)
  Female Reference
Current*,† CDC category 0.05
  N/A Reference
  B 0.67 (0.30–1.51)
  C 1.97 (0.84–4.60)
Cumulative duration of boosted 
protease inhibitor use
0.04
  0, y Reference
  1–4, y 1.80 (0.70–4.64)
  5–8, y 3.97 (1.54–10.24)
  >8, y 1.75 (0.65–4.71)
Ever tenofovir disoproxil fumarate 
use
0.02
  Yes 0.43 (0.22–0.87)
  No Reference
CDC indicates Centers for Disease Control and Prevention (N/A, not/mildly 
symptomatic; B, moderately symptomatic; C, severely symptomatic/AIDS 
definition); CI, confidence interval; and PDAY, Pathobiological Determinants of 
Atherosclerosis in Youth.
*Current is defined as the measurement at the most recent visit.
†A significant association was seen for current CDC category C relative to 
category B (multivariable odds ratio, 2.94; 95% CI, 1.23–7.05).
Table 5. Predictors of Abdominal Aorta PDAY Risk Scores ≥1 
Versus 0 Among the 165 Perinatally HIV-Infected Children in 
the Study Population at Their Most Recent Visit
Characteristic
Multivariable
Odds Ratio (95% CI) P Value
Current* HIV viral load 0.04
  ≤400, copies/mL Reference
  401–5000, copies/mL 0.08 (0.01–0.67)
  >5000, copies/mL 0.45 (0.14–1.40)
Current*† CDC category 0.04
  N/A Reference
  B 0.30 (0.09–1.02)
  C 1.37 (0.49–3.82)
Cumulative duration of boosted 
protease inhibitor use
<0.01
  0, y Reference
  1–4, y 0.70 (0.15–3.28)
  5–8, y 5.85 (1.62–21.17)
  >8, y 3.82 (0.92–15.78)
Current* abacavir use 0.30
  Yes 1.77 (0.60–5.27)
  No Reference
Current* lamivudine use 0.21
  Yes 2.19 (0.65–7.43)
  No Reference
Ever tenofovir disoproxil fumarate 
use
0.57
  Yes 0.75 (0.28–2.03)
  No Reference
CDC indicates Centers for Disease Control and Prevention (N/A, not/mildly 
symptomatic; B, moderately symptomatic; C, severely symptomatic/AIDS 
definition); CI, confidence interval; and PDAY, Pathobiological Determinants of 
Atherosclerosis in Youth.
*Current is defined as the measurement at the most recent visit.
†A significant association was seen for current CDC category C relative to 
category B (multivariable odds ratio, 4.59; 95% CI, 1.42–14.78).
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Figure 2. Pathobiological Determinants of 
Atherosclerosis in Youth (PDAY) risk scores 
over the study follow-up.
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in identifying and tracking such high-risk adolescents. Our 
findings suggest that lifestyle modifications (eg, diet and 
exercise) and switching to new antiretroviral regimens less 
likely to cause metabolic abnormalities should be consid-
ered.40 Finally, our study contributes to growing literature 
showing increased global risk for premature CVD disease 
morbidity and mortality in the perinatally HIV-infected 
population, including risk of cardiomyopathy and cardio-
metabolic disease.7–15,41,42 A comprehensive assessment and 
treatment plan based on validated screening and interven-
tions may be useful for those at highest risk in the perinatally 
HIV-infected population.
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CLINICAL PeRSPeCTIVe
Previous studies of perinatally HIV-infected children and adolescents raised concern about increased or accelerated risk of 
cardiovascular disease resulting from adverse distributions of individual atherosclerotic risk factors such as hyperlipidemia, 
insulin resistance, and body fat. For the first time, composite cardiovascular risk scores have been calculated for these 
 HIV-infected youth using the previously validated Pathobiological Determinants of Atherosclerosis in Youth (PDAY) scor-
ing system. These aggregate scores integrate a number of modifiable cardiovascular disease risk factors such as dyslipidemia, 
smoking, hypertension, obesity, and hyperglycemia. Forty-eight percent and 24% of our youth had high coronary arteries 
and abdominal aorta PDAY scores, respectively, identifying high-risk youth who may benefit from early lifestyle or clinical 
interventions. We additionally found HIV disease severity and ritonavir-boosted protease inhibitor use to significantly pre-
dict high scores, suggesting that switching to new antiretroviral regimens less likely to cause metabolic abnormalities should 
be considered for youth with increased atherosclerotic risk factor burden. Finally, our study contributes to growing literature 
showing increased global risk for premature cardiovascular disease morbidity and mortality in the perinatally  HIV-infected 
population, including risk of cardiomyopathy, leading to heart failure, and risk of cardiometabolic disease, leading to ath-
erosclerotic disease. A comprehensive assessment and treatment plan based on validated screening and interventions may be 
useful for those at highest cardiovascular disease risk in the perinatally HIV-infected population.
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1 
 
SUPPLEMENTAL MATERIAL 
 
2 
 
 
Supplemental Table 1. Enrollment characteristics of youth ≥ 15 years of age at their most 
recent visit in AMP, by inclusion in final study population. 
 
  
Characteristic 
Included 
n=165 
Excluded 
n=60 
Age, years 
     Mean (SD) 
 
13.8 (1.1) 
 
12.3 (1.4) 
Race/ethnicity, n (%) 
     White/Other 
     Black 
     Hispanic 
     Missing 
 
12 (7) 
113 (64) 
39 (24) 
1 (1) 
 
4 (7) 
38 (63) 
18 (30) 
0 (0) 
Female, n (%) 84 (51) 32 (53) 
CD4 count, cells/mm3 
     Mean (SD) 
     Missing  
 
626 (317) 
19 
 
747 (366) 
5 
HIV RNA, copies/mL 
     Median (Q1, Q3) 
     Missing 
 
400 (50, 2710) 
2 
 
400 (75, 1320) 
1 
 
Of the 451 youth enrolled in the original AMP protocol, 225 were in the validated age range for 
the PDAY score.  165 of the 225 had the necessary data to calculate PDAY scores.  
Comparison of demographic and clinical characteristics at enrollment between the 165 youth in 
our study population and the 60 youth who were excluded due to missing outcome information 
is presented above.  Those excluded from the study population were younger and had higher 
CD4 counts than those included in the study population.  Please note that while a difference 
was observed in CD4 count between those included and excluded in the study population, the 
mean CD4 counts for both groups were within normal ranges.   
  
3 
 
Supplemental Table 2. Distribution of modifiable atherosclerotic risk factors by PDAY 
scores. 
 
  CA Scores AA Scores 
Risk Factor 
Total 
n=165 
Low 
n=85 
High 
n=80 
Low 
n=126 
High 
n=39 
Modifiable risk factors, n (%)      
Non-HDL cholesterol, mg/dL 
     <130 
     130-159 
     160-189 
     190-219 
     ≥220 
 
128 (78) 
24 (14) 
12 (7) 
1 (1) 
0 (0) 
 
85 (100) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
43 (54) 
24 (30) 
12 (15) 
1 (1) 
0 (0) 
 
126 (100) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
2 (5) 
24 (61) 
12 (31) 
1 (3) 
0 (0) 
HDL cholesterol, mg/dL 
     <40 
     40-59 
     ≥60 
 
48 (29) 
96 (58) 
21 (13) 
 
0 (0) 
69 (81) 
16 (19) 
 
48 (60) 
27 (34) 
5 (6) 
 
40 (32) 
70 (55) 
16 (13) 
 
8 (20) 
26 (67) 
5 (13) 
Heavy smoking† 
     No 
     Yes 
 
165 (100) 
0 (0) 
 
85 (100) 
0 (0) 
 
80 (100) 
0 (0) 
 
126 (100) 
0 (0) 
 
39 (100) 
0 (0) 
Blood pressure‡ 
     Not hypertensive 
     Hypertensive 
 
163 (99) 
2 (1) 
 
85 (100) 
0 (0) 
 
78 (98) 
2 (2) 
 
126 (100) 
0 (0) 
 
37 (95) 
2 (5) 
Obesity (BMI), kg/m2 
   Male 
     ≤30 
     >30 
   Female 
     ≤30 
     >30 
 
 
74 (45) 
7 (4) 
 
70 (42) 
14 (9) 
 
 
35 (41) 
0 (0) 
 
38 (45) 
12 (14) 
 
 
39 (49) 
7 (9) 
 
32 (40) 
2 (2) 
 
 
56 (44) 
3 (2) 
 
55 (44) 
12 (10) 
 
 
18 (46) 
4 (10) 
 
15 (39) 
2 (5) 
Glycemia§ 
     Not hyperglycemic 
     Hyperglycemic      
 
163 (99) 
2 (1) 
 
85 (0) 
0 (0) 
 
78 (98) 
2 (2) 
 
126 (0) 
0 (0) 
 
37 (95) 
2 (5) 
*Adapted from McMahan et al. 2005.18 Copyright © 2005, American Medical Association. 
All rights reserved. 
†A heavy smoker was defined as smoking an average of at least one pack/day in the past 
3 months. 
‡Hypertensive was defined as an average systolic and/or diastolic blood pressure ≥95th 
percentile for age, sex, and height at three or more visits.  
§Hyperglycemic was defined as a fasting plasma glucose concentration ≥126 mg/dL, a 
diagnosis of diabetes, or using diabetes medication. 
 
HDL: high-density lipoprotein, BMI: body mass index 
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Supplemental Table 3. Demographic and clinical characteristics of the 165 perinatally 
HIV-infected children in the study population stratified by PDAY risk score at their most 
recent visit. 
 
 
 Coronary Arteries 
PDAY Score   
Abdominal Aorta 
PDAY Score 
 
Characteristic 
Total 
(n=165) 
≤0 
(n=85) 
≥1 
(n=80) P* 
0 
(n=126) 
≥1 
(n=39) P* 
Current† age, years, 
median (q1, q3) 
16.7  
(15.9, 17.8) 
16.7  
(15.7, 17.5) 
16.8  
(16.1, 17.9) 
0.12 
16.7  
(15.8, 17.7) 
17.1  
(15.9, 18.1) 
0.19 
        
Female, n (%) 84 (51%) 50 (59%) 34 (43%) 0.04 67 (53%) 17 (44%) 0.36 
        
Race/Ethnicity, n (%)    0.34   0.72 
  White/Other 12 (7%) 7 (8%) 5 (6%) 
 
9 (7%) 3 (8%) 
 
  Black 113 (68%) 61 (72%) 52 (65%) 88 (70%) 25 (64%) 
  Hispanic 39 (24%) 16 (19%) 23 (29%) 28 (22%) 11 (28%) 
  Missing 1 (1%) 1 (1%) 0 (0%) 1 (1%) 0 (0%) 
        
Current† CD4 count, 
cells/mm3, n (%) 
   0.59   0.20 
  <200 19 (12%) 8 (9%) 11 (14%) 
 
15 (12%) 4 (10%) 
 
  200-500 46 (28%) 26 (31%) 20 (25%) 39 (31%) 7 (18%) 
  >500 94 (57%) 49 (58%) 45 (56%) 67 (53%) 27 (69%) 
  Missing 6 (4%) 2 (2%) 4 (5%) 5 (4%) 1 (3%) 
        
Nadir CD4 count, 
cells/mm3, n (%) 
   0.95   0.93 
  <200 68 (41%) 34 (40%) 34 (43%) 
 
51 (40%) 17 (44%) 
   200-500 81 (49%) 43 (51%) 38 (48%) 62 (49%) 19 (49%) 
  >500 16 (10%) 8 (9%) 8 (10%) 13 (10%) 3 (8%) 
        
Current† viral load, 
copies/mL, n (%) 
   0.65   0.01 
  ≤400 98 (59%) 49 (58%) 49 (61%) 
 
68 (54%) 30 (77%) 
 
  401-5,000 25 (15%) 15 (18%) 10 (13%) 24 (19%) 1 (3%) 
  >5,000 35 (21%) 17 (20%) 18 (23%) 29 (23%) 6 (15%) 
  Missing 7 (4%) 4 (5%) 3 (4%) 5 (4%) 2 (5%) 
        
Peak viral load, 
copies/mL, n (%) 
   0.96   0.28 
  <10,000 7 (4%) 4 (5%) 3 (4%) 
 
4 (3%) 3 (8%) 
   10,000-100,000 45 (27%) 24 (28%) 21 (26%) 37 (29%) 8 (21%) 
  >100,000 113 (68%) 57 (67%) 56 (70%) 85 (67%) 28 (72%) 
        
Current† CDC 
category, n (%) 
   
0.05 
  
0.06 
  N/A 59 (36%) 33 (39%) 26 (33%) 
 
47 (37%) 12 (31%) 
   B 55 (33%) 33 (39%) 22 (28%) 46 (37%) 9 (23%) 
  C 51 (31%) 19 (22%) 32 (40%) 33 (26%) 18 (46%) 
HAART        
  Current† use, n (%) 143 (87%) 72 (85%) 71 (89%) 0.50 105 (83%) 38 (97%) 0.03 
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 Coronary Arteries 
PDAY Score   
Abdominal Aorta 
PDAY Score 
 
Characteristic 
Total 
(n=165) 
≤0 
(n=85) 
≥1 
(n=80) P* 
0 
(n=126) 
≥1 
(n=39) P* 
  Ever use, n (%) 160 (97%) 81 (95%) 79 (99%) 0.37 121 (96%) 39 (100%) 0.59 
  Cumulative duration 
of use, years, 
median (q1, q3) 
11.0  
(7.7, 12.5) 
10.9  
(7.6, 12.6) 
11.3  
(8.2, 12.5) 
0.81 
10.8  
(7.6, 12.6) 
11.3  
(8.2, 12.4) 
0.74 
        
Boosted protease 
inhibitor 
       
  Current† use, n (%) 95 (58%) 41 (48%) 54 (68%) 0.02 63 (50%) 32 (82%) <.01 
  Ever use, n (%) 122 (74%) 56 (66%) 66 (83%) 0.02 88 (70%) 34 (87%) 0.04 
  Cumulative duration 
of use, years, 
median (q1, q3) 
4.0  
(0.0, 7.4) 
2.8  
(0.0, 7.5) 
4.8  
(1.3, 7.3) 
0.09 
3.2  
(0.0, 7.3) 
6.0  
(4.5, 8.2) 
<.01 
        
Lopinavir/ritonavir        
  Current† use, n (%) 48 (29%) 18 (21%) 30 (38%) 0.03 26 (21%) 22 (56%) <.01 
  Ever use, n (%) 95 (58%) 42 (49%) 53 (66%) 0.04 66 (52%) 29 (74%) 0.02 
  Cumulative duration 
of use, years, 
median (q1, q3) 
1.4  
(0.0, 4.8) 
0.0  
(0.0, 4.6) 
2.1  
(0.0, 5.4) 
0.11 
0.4  
(0.0, 4.1) 
4.5  
(0.0, 6.8) 
<.01 
        
Indinavir        
  Current† use, n (%) 0 (0%) 0 (0%) 0 (0%) 1.00 0 (0%) 0 (0%) 1.00 
  Ever use, n (%) 18 (11%) 8 (9%) 10 (13%) 0.62 13 (10%) 5 (13%) 0.77 
  Cumulative duration 
of use, years, 
median (q1, q3) 
0.0  
(0.0, 0.0) 
0.0  
(0.0, 0.0) 
0.0  
(0.0, 0.0) 
0.61 
0.0  
(0.0, 0.0) 
0.0  
(0.0, 0.0) 
0.73 
        
Didanosine        
  Current† use, n (%) 17 (10%) 8 (9%) 9 (11%) 0.80 12 (10%) 5 (13%) 0.55 
  Ever use, n (%) 138 (84%) 74 (87%) 64 (80%) 0.29 105 (83%) 33 (85%) 1.00 
  Cumulative duration 
of use, years, 
median (q1, q3) 
3.3  
(1.0, 7.1) 
2.7  
(1.0, 7.5) 
3.7  
(1.1, 6.4) 
0.89 
2.9  
(0.9, 7.2) 
3.9  
(2.0, 6.6) 
0.26 
        
Abacavir        
  Current† use, n (%) 46 (28%) 23 (27%) 23 (29%) 0.86 29 (23%) 17 (44%) 0.02 
  Ever use, n (%) 79 (48%) 38 (45%) 41 (51%) 0.44 58 (46%) 21 (54%) 0.46 
  Cumulative duration 
of use, years, 
median (q1, q3) 
0.0  
(0.0, 3.3) 
0.0  
(0.0, 2.7) 
0.1  
(0.0, 4.3) 
0.18 
0.0  
(0.0, 2.7) 
0.4  
(0.0, 5.6) 
0.11 
        
Stavudine        
  Current† use, n (%) 11 (7%) 5 (6%) 6 (8%) 0.76 9 (7%) 2 (5%) 1.00 
  Ever use, n (%) 136 (82%) 69 (81%) 67 (84%) 0.69 104 (83%) 32 (82%) 1.00 
  Cumulative duration 
of use, years, 
median (q1, q3) 
6.1  
(1.8, 8.5) 
6.5  
(1.5, 8.5) 
5.7  
(2.8, 8.5) 
0.85 
6.1  
(1.7, 8.5) 
5.6  
(3.0, 8.5) 
0.99 
        
Zidovudine        
  Current† use, n (%) 18 (11%) 7 (8%) 11 (14%) 0.32 11 (9%) 7 (18%) 0.14 
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 Coronary Arteries 
PDAY Score   
Abdominal Aorta 
PDAY Score 
 
Characteristic 
Total 
(n=165) 
≤0 
(n=85) 
≥1 
(n=80) P* 
0 
(n=126) 
≥1 
(n=39) P* 
  Ever use, n (%) 145 (88%) 76 (89%) 69 (86%) 0.64 111 (88%) 34 (87%) 1.00 
  Cumulative duration 
of use, years, 
median (q1, q3) 
3.7  
(1.6, 7.4) 
3.7  
(1.7, 7.5) 
3.8  
(1.4, 7.4) 
0.94 
3.6  
(1.5, 7.5) 
3.9  
(1.9, 7.4) 
0.78 
        
Lamivudine         
  Current† use, n (%) 53 (32%) 25 (29%) 28 (35%) 0.51 35 (28%) 18 (46%) 0.05 
  Ever use, n (%) 149 (90%) 77 (91%) 72 (90%) 1.00 112 (89%) 37 (95%) 0.36 
  Cumulative duration 
of use, years, 
median (q1, q3) 
5.7  
(2.8, 9.4) 
5.7  
(3.9, 9.6) 
6.1  
(2.2, 9.2) 
0.54 
6.1 
 (2.8, 9.4) 
4.9  
(2.1, 10.7) 
0.64 
        
Tenofovir disoproxil 
fumarate  
       
  Current† use, n (%) 80 (48%) 45 (53%) 35 (44%) 0.28 64 (51%) 16 (41%) 0.36 
  Ever use, n (%) 100 (61%) 58 (68%) 42 (53%) 0.06 81 (64%) 19 (49%) 0.09 
  Cumulative duration 
of use, years, 
median (q1, q3) 
0.9  
(0.0, 3.2) 
1.0  
(0.0, 3.0) 
0.8  
(0.0, 3.3) 
0.44 
1.0  
(0.0, 3.3) 
0.0  
(0.0, 3.1) 
0.23 
* Wilcoxon Test p-value for continuous variables and Fisher's Exact Test p-value for categorical 
variables. 
†Current defined as measurement at most recent visit. 
 
CDC: Centers for Disease Control and Prevention (N/A: not/mildly symptomatic, B: moderately 
symptomatic, C: severely symptomatic (AIDS definition)), HAART: highly active antiretroviral therapy. 
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Sensitivity analyses restricting our population to treated and suppressed children are presented 
below.  Our study population decreased to N=98 children who were virologically suppressed (VL 
≤ 400 copies/mL).  The prevalence of high CA and AA scores in this subset was 50% (N=49 
with CA scores ≥1) and 31% (N=30 with AA scores ≥1), respectively.  As expected given 
observed associations between PI exposure and CVD risk factors, the prevalence of high PDAY 
scores in the virologically suppressed subset was larger than the prevalence observed in the 
overall study population (48% with high CA scores and 24% with high AA scores in the overall 
study population, N=165).     
 
 
Supplemental Table 4.  Predictors of coronary arteries PDAY risk scores ≥1 versus ≤0 
among the 98 virologically suppressed perinatally HIV-infected children in the study 
population at their most recent visit. 
 
Characteristic Multivariable 
Odds Ratio (95% CI) 
 
P 
Sex  0.02 
     Male 3.05 (1.24, 7.54) 
 
     Female Reference 
Current*,† CDC category  0.03 
     N/A Reference 
      B 0.53 (0.18, 1.52) 
     C 2.37 (0.83, 6.79) 
Current lopinavir/ritonavir use*  0.05 
     Yes 2.54 (1.02, 6.34) 
 
     No Reference 
*Current defined as measurement at most recent visit. 
†A significant association was seen for current CDC category C relative to category B -
multivariable odds ratio (95% CI):  4.49 (1.45, 13.91). 
 
CDC:  Centers for Disease Control and Prevention (N/A: not/mildly symptomatic, B: moderately 
symptomatic, C: severely symptomatic (AIDS definition)). 
 
- Consistent with the results observed in the overall study population, male sex and having an 
AIDS indicator condition (CDC C category), predicted high CA scores.  Instead of duration of 
boosted PI use however, current use of lopinavir/ritonavir was a stronger predictor of high CA 
scores in the virologically suppressed subset.  Tenofovir use also did not significantly predict 
high CA scores in the virologically suppressed sub-population, which is still in contrast to the 
recent study highlighted in the discussion section finding tenofovir to be significantly associated 
with progression of subclinical atherosclerosis among HIV-infected adults.  
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Supplemental Table 5.  Predictors of abdominal aorta PDAY risk scores ≥1 versus 0 
among the 98 virologically suppressed perinatally HIV-infected children in the study 
population at their most recent visit. 
 
Characteristic Multivariable 
Odds Ratio (95% CI) 
 
P 
Cumulative duration of boosted 
protease inhibitor use, years 
 
0.03 
     0 Reference 
 
     1-4 0.63 (0.13, 3.08) 
    5-8 4.33 (1.23, 15.26)  
     >8 2.35 (0.57, 9.76)  
Current* abacavir use  0.03 
     Yes 3.06 (1.13, 8.25) 
 
     No Reference 
*Current defined as measurement at most recent visit. 
 
- Consistent with the results observed in the overall study population, a longer duration of 
boosted PI use significantly predicted high AA scores.  However, in the virologically suppressed 
subset, CDC category did not significantly predict high AA scores, suggesting that the effect of 
past HIV severity may be mitigated by subsequent use of ART.  In the subset analysis, current 
abacavir use significantly predicted high AA scores.  This finding is consistent with some studies 
in HIV-infected adults reporting increased rates of myocardial infarctions with abacavir use.  We 
note, however, that the literature on the association between abacavir use and CVD is 
conflicting and would like to stress that our study was not aimed at specifically assessing this 
association, but rather it focused on identifying predictors of aggregate CVD risk measured at 
one point in time. 
